Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Research & Development (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Research & Development for 13 consecutive years, with $88.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 6.33% year-over-year to $88.1 million, compared with a TTM value of $339.5 million through Dec 2025, up 12.7%, and an annual FY2025 reading of $339.5 million, up 12.7% over the prior year.
  • Research & Development was $88.1 million for Q4 2025 at Agios Pharmaceuticals, up from $86.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $91.9 million in Q2 2025 and bottomed at $57.7 million in Q1 2021.
  • Average Research & Development over 5 years is $73.7 million, with a median of $72.6 million recorded in 2024.
  • The sharpest move saw Research & Development surged 243.96% in 2021, then decreased 11.47% in 2024.
  • Year by year, Research & Development stood at $73.3 million in 2021, then decreased by 4.09% to $70.3 million in 2022, then increased by 10.23% to $77.5 million in 2023, then rose by 6.87% to $82.8 million in 2024, then increased by 6.33% to $88.1 million in 2025.
  • Business Quant data shows Research & Development for AGIO at $88.1 million in Q4 2025, $86.8 million in Q3 2025, and $91.9 million in Q2 2025.